Since tyrosine kinase inhibitors targeting the HGF/MET pathway have already been studied in MET-positive GC with no substantial benefit [26], we evaluated the potential of EM127 as a sensitizing agent as part of a synergistic approach with SU11274. Here, MET is linked to gastric cancer.